D'ARMINIO MONFORTE, ANTONELLA
 Distribuzione geografica
Continente #
NA - Nord America 13.032
EU - Europa 10.205
AS - Asia 2.465
AF - Africa 448
SA - Sud America 205
OC - Oceania 170
Continente sconosciuto - Info sul continente non disponibili 23
Totale 26.548
Nazione #
US - Stati Uniti d'America 12.702
DE - Germania 4.586
IT - Italia 1.842
CN - Cina 1.353
FR - Francia 1.306
GB - Regno Unito 787
CA - Canada 280
IN - India 232
NL - Olanda 215
ES - Italia 190
KR - Corea 164
AU - Australia 163
RU - Federazione Russa 161
ZA - Sudafrica 141
IE - Irlanda 134
DK - Danimarca 129
UA - Ucraina 124
CH - Svizzera 121
ET - Etiopia 116
JP - Giappone 114
TH - Thailandia 81
BR - Brasile 77
CZ - Repubblica Ceca 75
NO - Norvegia 70
FI - Finlandia 69
ID - Indonesia 69
TW - Taiwan 61
HK - Hong Kong 58
SE - Svezia 54
EU - Europa 51
RO - Romania 48
CL - Cile 46
GR - Grecia 45
MY - Malesia 45
PT - Portogallo 44
PL - Polonia 42
IR - Iran 41
BE - Belgio 40
TR - Turchia 36
AE - Emirati Arabi Uniti 34
NG - Nigeria 32
VN - Vietnam 32
MX - Messico 30
AR - Argentina 26
UG - Uganda 26
HR - Croazia 24
CO - Colombia 22
SG - Singapore 22
PH - Filippine 20
KE - Kenya 19
LT - Lituania 19
PE - Perù 18
PK - Pakistan 18
AT - Austria 16
EG - Egitto 15
SA - Arabia Saudita 15
ZM - Zambia 14
HU - Ungheria 13
MK - Macedonia 13
IQ - Iraq 12
ZW - Zimbabwe 11
BW - Botswana 10
GE - Georgia 10
IL - Israele 10
GH - Ghana 8
CM - Camerun 7
LU - Lussemburgo 7
NZ - Nuova Zelanda 7
TN - Tunisia 7
AL - Albania 5
EC - Ecuador 5
GY - Guiana 5
LB - Libano 5
MA - Marocco 5
RS - Serbia 5
SK - Slovacchia (Repubblica Slovacca) 5
A1 - Anonimo 4
BG - Bulgaria 4
BJ - Benin 4
DZ - Algeria 4
NA - Namibia 4
AN - Antille olandesi 3
CR - Costa Rica 3
CY - Cipro 3
ER - Eritrea 3
IS - Islanda 3
JO - Giordania 3
KH - Cambogia 3
MQ - Martinica 3
NP - Nepal 3
SR - Suriname 3
SZ - Regno dello Swaziland 3
TZ - Tanzania 3
AM - Armenia 2
BD - Bangladesh 2
BS - Bahamas 2
CD - Congo 2
CI - Costa d'Avorio 2
HN - Honduras 2
KW - Kuwait 2
Totale 26.534
Città #
Fairfield 1.428
Ashburn 941
Seattle 916
Houston 783
Woodbridge 755
Milan 742
Buffalo 714
Beijing 581
Santa Cruz 501
Cambridge 469
Wilmington 425
Ann Arbor 350
Nürnberg 295
Mountain View 252
Munich 203
Southend 160
Chicago 143
Kiez 134
Shanghai 128
Dublin 127
Boardman 115
Rome 115
Los Angeles 107
San Diego 106
Las Vegas 98
Redmond 95
University Park 94
Phoenix 88
Leawood 79
Muizenberg 78
Clearwater 76
Wuhan 76
New York 73
Ottawa 71
London 64
Dallas 63
Helsinki 57
Lyngby 54
Taipei 52
Hangzhou 48
Paris 48
Guangzhou 46
Atlanta 45
Bengaluru 45
Montréal 44
Fleming Island 43
Henderson 43
San Francisco 40
Riva 39
Council Bluffs 37
Sydney 37
Barcelona 36
Brooklyn 36
Des Moines 36
Toronto 36
Oslo 34
Milpitas 30
Mumbai 29
Provo 29
Zurich 28
Madrid 27
Rotterdam 27
Amsterdam 26
Athens 25
Copenhagen 23
Fremont 23
Herndon 23
Bangkok 22
Chengdu 22
Palermo 22
Portland 22
Tokyo 22
Turin 22
Berlin 21
Scranton 21
Zagreb 21
Central 20
Nanjing 20
Seoul 20
Access 19
Easton 19
Madison 19
Washington 19
Bern 18
Stockholm 18
Genoa 17
Melbourne 17
Montreal 17
Stanford 17
Lake Forest 16
Saint Petersburg 16
San Jose 16
Brescia 15
Duncan 15
Durban 15
Eau Claire 15
Padova 15
Santiago 15
Singapore 15
Austin 14
Totale 13.193
Nome #
Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy, file dfa8b98e-1b78-748b-e053-3a05fe0a3a96 1.460
Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy : an international observational study, file dfa8b98e-1b86-748b-e053-3a05fe0a3a96 1.142
All-cause mortality in treated HIV-infected adults with CD4 500/mm3 compared with the general population : evidence from a large European observational cohort collaboration, file dfa8b990-b661-748b-e053-3a05fe0a3a96 765
Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens, file dfa8b98f-fb18-748b-e053-3a05fe0a3a96 646
Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006 : collaborative analysis of 13 HIV cohort studies, file dfa8b990-1261-748b-e053-3a05fe0a3a96 636
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries, file dfa8b98f-7852-748b-e053-3a05fe0a3a96 473
The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection, file dfa8b990-40e4-748b-e053-3a05fe0a3a96 458
Performance of genotypic tropism testing on proviral DNA in clinical practice : results from the DIVA study group, file dfa8b990-1874-748b-e053-3a05fe0a3a96 452
Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study)., file dfa8b9a5-77a7-748b-e053-3a05fe0a3a96 435
Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients, file dfa8b990-c4f4-748b-e053-3a05fe0a3a96 395
Detrimental effect of atazanavir plasma concentrations on total serum bilirubin levels in the presence of UGT1A1 polymorphisms, file dfa8b98f-f3fd-748b-e053-3a05fe0a3a96 384
Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors, file dfa8b98e-1b54-748b-e053-3a05fe0a3a96 378
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen, file dfa8b99f-cd0c-748b-e053-3a05fe0a3a96 339
Italian consensus statement on management of HIV-infected individuals with advanced disease naive to antiretroviral therapy, file dfa8b98e-bbc6-748b-e053-3a05fe0a3a96 337
Risk of tuberculosis following HIV seroconversion in high-income countries, file dfa8b990-8f64-748b-e053-3a05fe0a3a96 322
Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus, file dfa8b9aa-33d0-748b-e053-3a05fe0a3a96 305
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy, file dfa8b991-2432-748b-e053-3a05fe0a3a96 296
What do the changing patterns of comorbidity burden in people living with HIV mean for long-term management? Perspectives from European HIV cohorts, file dfa8b9a4-dd83-748b-e053-3a05fe0a3a96 293
Reduced central memory CD4+ T cells and increased T-Cell activation characterise treatment-naive patients newly diagnosed at late stage of HIV infection, file dfa8b990-0a94-748b-e053-3a05fe0a3a96 281
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART, file dfa8b99e-1181-748b-e053-3a05fe0a3a96 275
One‐Year Cognitive Follow‐Up of COVID‐19 Hospitalized Patients, file 716b720a-6f43-4058-9740-62df85c978d5 272
Virologic and Immunologic Response to cART by HIV-1 Subtype in the CASCADE Collaboration, file dfa8b990-c4f5-748b-e053-3a05fe0a3a96 259
Survival outcomes and effect of early vs. deferred cART among HIV-infected patients diagnosed at the time of an AIDS-defining event: a cohort analysis, file dfa8b98f-a3ee-748b-e053-3a05fe0a3a96 247
Late presentation of HIV infection : a consensus definition, file dfa8b99d-83bf-748b-e053-3a05fe0a3a96 244
Is the rate of virological failure to cART continuing to decline in recent calendar years?, file dfa8b99e-53f0-748b-e053-3a05fe0a3a96 238
Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients, file dfa8b990-09e0-748b-e053-3a05fe0a3a96 236
Free light chains and the risk of nonmalignant AIDS events in HIV-infected patients treated with combination antiretroviral therapy, file dfa8b990-c3ee-748b-e053-3a05fe0a3a96 223
Effectiveness of switching to darunavir/cobicistat in virologically-suppressed HIV-positive patients receiving ritonavir-boosted protease inhibitor-based regimen : the "STORE" Study, file dfa8b9a1-3b51-748b-e053-3a05fe0a3a96 212
Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+ :  CD8+ ratio, file dfa8b99b-327c-748b-e053-3a05fe0a3a96 210
T-Cell Phenotypes, Apoptosis and Inflammation in HIV+ Patients on Virologically Effective cART with Early Atherosclerosis, file dfa8b990-68f7-748b-e053-3a05fe0a3a96 209
Hepatitis c virus viremia increases the Incidence of chronic kidney disease in HIV-infected Patients, file dfa8b9a3-d5e4-748b-e053-3a05fe0a3a96 208
Increased risk of cardiovascular disease (CVD) with age in HIV-positive men : a comparison of the D: A: D CVD risk equation and general population CVD risk equations, file dfa8b99d-f8de-748b-e053-3a05fe0a3a96 207
Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America, file dfa8b992-65fb-748b-e053-3a05fe0a3a96 206
Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV : a multilevel analysis, file dfa8b990-0a10-748b-e053-3a05fe0a3a96 197
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population, file dfa8b9a3-2f62-748b-e053-3a05fe0a3a96 192
Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression : 48-week efficacy and safety results, file dfa8b991-92f4-748b-e053-3a05fe0a3a96 190
Cause-specific mortality in HIV-positive patients who survived ten years after starting antiretroviral therapy, file dfa8b99a-97f6-748b-e053-3a05fe0a3a96 188
Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients : results from the Icona Foundation study, file dfa8b991-2431-748b-e053-3a05fe0a3a96 186
Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals : The D: A: D Study, file dfa8b990-bbf6-748b-e053-3a05fe0a3a96 184
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort, file dfa8b99d-254b-748b-e053-3a05fe0a3a96 184
Stimulation of PBMC and Monocyte-Derived Macrophages via Toll-Like Receptor Activates Innate Immune Pathways in HIV-Infected Patients on Virally Suppressive Combination Antiretroviral Therapy, file dfa8b99c-9cac-748b-e053-3a05fe0a3a96 176
Predicting the short-term risk of diabetes in HIV-positive patients : the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study, file dfa8b990-b610-748b-e053-3a05fe0a3a96 175
CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE, file dfa8b990-b88a-748b-e053-3a05fe0a3a96 175
Is weak CD4+ gain in the course of suppressive combination antiretroviral therapy for HIV infection a current clinical challenge? A case report and brief review of the literature, file dfa8b99a-32f8-748b-e053-3a05fe0a3a96 170
Improvement of ALT decay kinetics by all-oral HCV treatment : role of NS5A inhibitors and differences with IFN-based regimens, file dfa8b99d-cc34-748b-e053-3a05fe0a3a96 168
Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy, file dfa8b98f-a2e2-748b-e053-3a05fe0a3a96 164
Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A. : a modelling study, file dfa8b999-b521-748b-e053-3a05fe0a3a96 161
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy : 48-Week results of a randomized trial, file dfa8b999-d10e-748b-e053-3a05fe0a3a96 161
Feasibility and effectiveness of indicator condition-guided testing for HIV : results from HIDES I (HIV Indicator Diseases across Europe Study), file dfa8b990-bbf0-748b-e053-3a05fe0a3a96 160
Invariant Natural Killer T (iNKT) cells in HAART-treated, HIV-positive patients with bone and cardiovascular impairment, file dfa8b994-2f68-748b-e053-3a05fe0a3a96 152
Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA, file dfa8b9a3-8569-748b-e053-3a05fe0a3a96 151
HPV infection in a cohort of HIV-positive men and women : prevalence of oncogenic genotypes and predictors of mucosal damage at genital and oral sites, file dfa8b991-2442-748b-e053-3a05fe0a3a96 149
HIV-Infected late presenter patients, file dfa8b990-0eb6-748b-e053-3a05fe0a3a96 147
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011, file dfa8b990-16b4-748b-e053-3a05fe0a3a96 144
Increased bone marrow interleukin-7 (IL-7)/IL-7R levels but reduced IL-7 responsiveness in HIV-Positive patients lacking CD4+ gain on antiviral therapy, file dfa8b98f-7070-748b-e053-3a05fe0a3a96 142
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI, file dfa8b98f-a81f-748b-e053-3a05fe0a3a96 142
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals : an observational cohort study, file dfa8b99b-3097-748b-e053-3a05fe0a3a96 142
Predictors of having a resistance test following confirmed virological failure of cART: data from EuroSIDA, file dfa8b990-2059-748b-e053-3a05fe0a3a96 140
Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders, file dfa8b990-bc6c-748b-e053-3a05fe0a3a96 140
Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population, file dfa8b99a-fe6e-748b-e053-3a05fe0a3a96 140
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir± ribavirin in HIV/HCV co-infected patients, file dfa8b99e-1836-748b-e053-3a05fe0a3a96 140
Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals : The Antiretroviral Therapy Cohort Collaboration, file dfa8b9a5-5b25-748b-e053-3a05fe0a3a96 140
The effect of switching to Maraviroc + Darunavir/ritonavir dual therapy in virologically suppressed patients on the progression of liver fibrosis, file dfa8b99d-c416-748b-e053-3a05fe0a3a96 138
Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy : A postauthorization noninterventional study, file dfa8b996-43f7-748b-e053-3a05fe0a3a96 136
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus, file dfa8b99e-304b-748b-e053-3a05fe0a3a96 136
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts : Data from the Icona Foundation Cohort, file dfa8b996-5ad3-748b-e053-3a05fe0a3a96 133
Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration, file dfa8b99a-a481-748b-e053-3a05fe0a3a96 131
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus, file dfa8b996-bae8-748b-e053-3a05fe0a3a96 130
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection : Results of an Italian Compassionate Use Program, file dfa8b99d-e5d0-748b-e053-3a05fe0a3a96 130
Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients, file dfa8b9a3-bc70-748b-e053-3a05fe0a3a96 129
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice, file dfa8b996-c666-748b-e053-3a05fe0a3a96 128
Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe : results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE), file dfa8b99a-a7a3-748b-e053-3a05fe0a3a96 128
Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients, file dfa8b99e-0a40-748b-e053-3a05fe0a3a96 128
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy, file dfa8b99c-e6d5-748b-e053-3a05fe0a3a96 127
Role of in vitro stimulation with lipopolysaccharide on T-Cell activation in HIV-infected antiretroviral-treated patients, file dfa8b990-1871-748b-e053-3a05fe0a3a96 126
Cognitive Neuro-Rehabilitation of HIV-Associated Neurocognitive Disorders : Case Reports of A New Computer-Based Restorative Approach In 3 Hiv-Positive Cart-Treated Patients, file dfa8b999-5cce-748b-e053-3a05fe0a3a96 125
Timing of antiretroviral therapy initiation after a first AIDS-defining event : temporal changes in clinical attitudes in the ICONA cohort, file dfa8b991-2214-748b-e053-3a05fe0a3a96 124
Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy, file dfa8b997-4e36-748b-e053-3a05fe0a3a96 124
Illness Representations of HIV Positive Patients Are Associated with Virologic Success, file dfa8b997-cd06-748b-e053-3a05fe0a3a96 123
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIRaben-1 subtype B and non-subtype B receiving a salvage regimen, file dfa8b99a-65c5-748b-e053-3a05fe0a3a96 123
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens, file dfa8b99b-27ae-748b-e053-3a05fe0a3a96 121
Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk : a prospective analysis of the D:A:D observational study, file dfa8b99a-98d5-748b-e053-3a05fe0a3a96 120
Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study, file dfa8b99b-807b-748b-e053-3a05fe0a3a96 120
Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America, file dfa8b99b-ff30-748b-e053-3a05fe0a3a96 120
Mucosal cell populations may contribute to peripheral immune abnormalities in HIV-infected subjects introducing cART with moderate immune-suppression, file dfa8b99e-df6e-748b-e053-3a05fe0a3a96 120
Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort, file dfa8b99a-06eb-748b-e053-3a05fe0a3a96 119
An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy, file dfa8b99e-33e1-748b-e053-3a05fe0a3a96 117
A376s in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy, file dfa8b9a3-9b58-748b-e053-3a05fe0a3a96 116
Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies, file dfa8b998-a850-748b-e053-3a05fe0a3a96 114
Antiretroviral drugs and risk of chronic alanine aminotransferase elevation in human immunodeficiency virus (HIV)-monoinfected persons: The data collection on adverse events of Anti-HIV drugs study, file dfa8b99b-4d3d-748b-e053-3a05fe0a3a96 113
The EuroSIDA study: 25 years of scientific achievements, file dfa8b9aa-4331-748b-e053-3a05fe0a3a96 113
Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord, file dfa8b99a-a719-748b-e053-3a05fe0a3a96 112
A 20-year-old girl with an unusual febrile illness, file dfa8b9a6-fb4c-748b-e053-3a05fe0a3a96 112
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy, file dfa8b996-a8d3-748b-e053-3a05fe0a3a96 111
Therapeutic Effect of Iron Citrate in Blocking Calcium Deposition in High Pi-Calcified VSMC: Role of Autophagy and Apoptosis, file dfa8b9a0-3cb6-748b-e053-3a05fe0a3a96 110
High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects Data from the ICONA Foundation Cohort, file dfa8b99a-a117-748b-e053-3a05fe0a3a96 108
Psychological outcomes after hospitalization for COVID-19: data from a multidisciplinary follow-up screening program for recovered patients, file dfa8b9a5-0a33-748b-e053-3a05fe0a3a96 108
The Many Faces of Covid-19 at a Glance: A University Hospital Multidisciplinary Account From Milan, Italy, file dfa8b9a5-cd28-748b-e053-3a05fe0a3a96 107
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008 : data from the ICONA Foundation Study Cohort, file dfa8b99d-e5dc-748b-e053-3a05fe0a3a96 106
Association between abdominal aortic calcifications, bone mineral density and vertebral fractures in a cohort of HIV-positive patients, file dfa8b997-7b3b-748b-e053-3a05fe0a3a96 105
Totale 22.334
Categoria #
all - tutte 53.028
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.028


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.581 0 0 0 0 0 0 0 0 220 339 523 499
2019/20204.388 378 251 301 564 430 409 399 427 453 279 227 270
2020/20213.712 171 332 151 364 319 310 325 351 346 406 371 266
2021/20224.517 264 289 220 402 468 196 326 277 362 262 996 455
2022/20234.124 202 217 909 650 297 313 260 276 208 230 381 181
2023/20242.448 179 149 270 154 321 236 407 420 312 0 0 0
Totale 27.747